Insmed Inc

Insmed Inc is a global biopharmaceutical company specializing in the development and commercialization of therapies for serious and rare diseases. Founded in 1988, Insmed has built its reputation on a patient-centered approach, with a strong commitment to addressing critical unmet medical needs. The company is particularly recognized for its work in respiratory diseases, highlighted by its lead marketed product, Arikayce, a liposomal amikacin inhalation therapy indicated for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex in adults. Insmed’s research pipeline features innovative candidates such as brensocatib for non-cystic fibrosis bronchiectasis, and TPIP, an inhaled formulation targeting pulmonary arterial hypertension and related conditions. With operations spanning the United States, Europe, and Asia, Insmed plays a significant role in the rare disease therapeutics market. The company is known for leveraging proprietary drug delivery technologies and for advancing therapies through global regulatory environments, underlining its status as a leader in specialized biopharmaceutical innovation.